FY2025 EPS Estimates for Pfizer Boosted by Cantor Fitzgerald

Pfizer Inc. (NYSE:PFE - Free Report) - Research analysts at Cantor Fitzgerald increased their FY2025 earnings estimates for shares of Pfizer in a note issued to investors on Wednesday, April 30th. Cantor Fitzgerald analyst C. Gould now expects that the biopharmaceutical company will earn $3.10 per share for the year, up from their prior estimate of $2.99. Cantor Fitzgerald has a "Neutral" rating and a $24.00 price objective on the stock. The consensus estimate for Pfizer's current full-year earnings is $2.95 per share.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. During the same period last year, the business posted $0.82 earnings per share. Pfizer's revenue was down 7.8% on a year-over-year basis.

Several other equities analysts have also weighed in on the company. The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and an average price target of $29.64.

Pfizer Stock Performance

PFE traded up $0.26 during midday trading on Thursday, reaching $24.19. The company had a trading volume of 41,672,273 shares, compared to its average volume of 40,568,489. Pfizer has a 12-month low of $20.92 and a 12-month high of $31.54. The business has a 50-day moving average price of $24.34 and a two-hundred day moving average price of $25.78. The stock has a market cap of $137.19 billion, a PE ratio of 17.16, a P/E/G ratio of 0.64 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Institutional Trading of Pfizer

Several institutional investors have recently added to or reduced their stakes in the business. Patton Albertson Miller Group LLC lifted its stake in shares of Pfizer by 5.8% in the 1st quarter. Patton Albertson Miller Group LLC now owns 21,787 shares of the biopharmaceutical company's stock valued at $552,000 after acquiring an additional 1,199 shares during the last quarter. Retirement Planning Co of New England Inc. increased its stake in Pfizer by 649.7% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 185,136 shares of the biopharmaceutical company's stock worth $4,691,000 after purchasing an additional 160,441 shares during the period. Pzena Investment Management LLC lifted its position in Pfizer by 1.5% in the first quarter. Pzena Investment Management LLC now owns 7,058,981 shares of the biopharmaceutical company's stock valued at $178,875,000 after purchasing an additional 107,402 shares during the last quarter. Forum Financial Management LP boosted its stake in shares of Pfizer by 8.1% during the first quarter. Forum Financial Management LP now owns 104,496 shares of the biopharmaceutical company's stock valued at $2,648,000 after purchasing an additional 7,851 shares during the period. Finally, Easterly Investment Partners LLC grew its holdings in shares of Pfizer by 262.4% in the first quarter. Easterly Investment Partners LLC now owns 70,668 shares of the biopharmaceutical company's stock worth $1,791,000 after purchasing an additional 51,168 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares of the company's stock, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.11%. Pfizer's payout ratio is 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.